Whether Vimseltinib has been included in the reimbursement scope of national medical insurance?

Vimseltinib is a new oral CSF1R inhibitor, mainly used to treat diseases such as pigmented villonodular synovitis (TGCT). The drug has been approved by the US FDA in early 2025, but has not yet been officially approved for marketing in China. Therefore, the market access of vimsetinib in China is still in the waiting stage and has not yet entered the medical insurance catalog.

Since it has not been approved by the State Food and Drug Administration, vimsetinib has naturally not been included in China's National Reimbursement List (NRDL), and patients cannot reimburse the cost of the drug through medical insurance channels in China. This means that patients who need to use the drug can only purchase it through formal overseas channels, and their medical expenses cannot be subsidized by medical insurance.

In the future, as vimsetinib is promoted to be launched in China, whether it will be included in the medical insurance catalog will still need to be reviewed and price negotiated by the National Medical Insurance Bureau. Medical insurance inclusion usually considers the clinical value, price reasonableness and patient needs of the drug. It is expected that if vimsetinib is effective and affordable after its launch, it is expected to enter the medical insurance system, thus reducing the financial burden on patients.

For patients who urgently need to use vimsetinib, it is recommended to pay attention to clinical trial opportunities at home and abroad or obtain the drug through formal overseas medical channels. At the same time, patients should pay close attention to the latest announcements from the State Food and Drug Administration and the medical insurance department, keep abreast of dynamic adjustments to medical insurance reimbursement policies, and arrange treatment plans reasonably.

Reference materials:https://www.drugs.com/